Conference ReCAP

Diabetes and Heart Disease Highlights From ACC 2022


 

Cardiologist Martha Gulati, from the American Society for Preventive Cardiology, offers insight on the key findings in diabetes and heart disease presented at the 2022 annual meeting of the American College of Cardiology.

First, Dr Gulati shares updates from the SCORED trial, which looked at SGLT2 inhibitors and cardiovascular and renal event reduction in patients with type 2 diabetes and chronic kidney disease.

Next, she shares insight on CHAP, an important study about chronic hypertension in pregnancy. Researchers found that more aggressive blood pressure control reduced adverse pregnancy outcomes.

She then discusses the SuperWIN trial, which looked at various types of educational interventions regarding heart-healthy diet provided in supermarkets. The goal of this study was to assess adherence to the DASH diet.

Dr Gulati closes her report with the PROMPT-HF trial, which aimed at improving the use of guideline-directed medical therapy in outpatients with heart failure.

--

President, American Society for Preventive Cardiology, Jacksonville, Florida

Martha Gulati, MD, has disclosed no relevant financial relationships.

Recommended Reading

Prediabetes is linked independently to myocardial infarction
MDedge Cardiology
‘DIY’ artificial pancreas systems found to be safe, effective: CREATE trial
MDedge Cardiology
Exercise of any type boosts type 1 diabetes time in range
MDedge Cardiology
Diabetes tied to risk of long COVID, too
MDedge Cardiology
Heart failure: Medicare cost sharing may put quadruple therapy out of reach
MDedge Cardiology
Experts elevate new drugs for diabetic kidney disease
MDedge Cardiology
Ultra-processed: Doctors debate whether putting this label on foods is useful
MDedge Cardiology
New data, film highlight islet cell transplantation progress
MDedge Cardiology
Type 1 diabetes control worse in racially segregated teens
MDedge Cardiology
Cardiologists concerned for patient safety after abortion ruling
MDedge Cardiology